Pri­or­i­ty re­view for Take­da’s ul­tra-rare blood clot ERT; FDA to give an­oth­er look at Arde­lyx’s CKD drug

The FDA will re­view Take­da’s en­zyme re­place­ment ther­a­py for an ul­tra-rare blood clot­ting dis­or­der and de­cide whether to ap­prove it with­in six months, the Japan­ese …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.